SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

25 Oct 2024 Evaluate
The revenue zoomed 6.61% to Rs. 1826.46 millions for the quarter ended September 2024 as compared to Rs. 1713.15 millions during the corresponding quarter last year.A big decline of -49.71% was reported for the quarter ended September 2024 to Rs. 170.44  millions from Rs. 338.91 millions of corresponding previous quarter.The Operating Profit of the company witnessed a decrease to 337.34 millions from 529.22 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 1826.46 1713.15 6.61 3316.09 2803.07 18.30 6054.60 5983.40 1.19
Other Income 83.54 106.14 -21.29 151.95 171.41 -11.35 335.01 507.66 -34.01
PBIDT 337.34 529.22 -36.26 673.17 705.00 -4.51 1406.68 1409.21 -0.18
Interest 34.48 11.78 192.70 46.16 24.87 85.61 58.06 100.56 -42.26
PBDT 302.86 517.44 -41.47 627.01 680.13 -7.81 937.76 1308.65 -28.34
Depreciation 63.95 56.78 12.63 126.56 110.42 14.62 235.19 151.73 55.01
PBT 238.91 460.66 -48.14 500.45 569.71 -12.16 702.57 1156.92 -39.27
TAX 68.47 121.75 -43.76 135.80 155.84 -12.86 196.13 302.14 -35.09
Deferred Tax -18.97 1.29 -1570.54 -21.92 8.29 -364.41 -75.49 -42.10 79.31
PAT 170.44 338.91 -49.71 364.65 413.87 -11.89 506.44 854.78 -40.75
Equity 105.14 104.40 0.71 105.14 104.40 0.71 104.69 104.15 0.52
PBIDTM(%) 18.47 30.89 -40.21 20.30 25.15 -19.29 23.23 23.55 -1.35

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×